Zero Candida Technologies (TSXV:ZCT) 3-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:ZCT Zero Candida Technologies Inc TSXV:ZCT
15 GF Score
Price C$0.15
! 1 Warning Sign
View Full Analysis

What is Zero Candida Technologies 3-Year EBITDA Growth Rate?

Zero Candida Technologies TSXV:ZCT 15 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates TSXV:ZCT with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 689 Medical Devices & Instruments companies, Zero Candida Technologies ranks worse than 145137.74% on this metric.

Zero Candida Technologies's EBITDA per Share for the three months ended in Jun. 2026 was C$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Zero Candida Technologies  (TSXV:ZCT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Zero Candida Technologies 3-Year EBITDA Growth Rate Related Terms

TSXV:ZCT vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, Zero Candida Technologies's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zero Candida Technologies 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zero Candida Technologies's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Zero Candida Technologies's 3-Year EBITDA Growth Rate falls into.


TSXV:ZCT
15GF Score
Zero Candida Technologies Inc TSXV:ZCT
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zero Candida Technologies 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Zero Candida Technologies (TSXV:ZCT) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zero Candida Technologies and its competitors. According to the industry distribution chart, Zero Candida Technologies ranks #999999 out of 689 companies in the Medical Devices & Instruments industry.
Is Zero Candida Technologies' 3-Year EBITDA Growth Rate too high?
Zero Candida Technologies' current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Zero Candida Technologies ranks #999999 out of 689 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Zero Candida Technologies has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Zero Candida Technologies' 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zero Candida Technologies ranks #999999 out of 689 companies for 3-Year EBITDA Growth Rate. This places Zero Candida Technologies in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Zero Candida Technologies and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zero Candida Technologies's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zero Candida Technologies stock overvalued right now?
Zero Candida Technologies (TSXV:ZCT) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Zero Candida Technologies' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Zero Candida Technologies (TSXV:ZCT), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zero Candida Technologies Business Description

Address 666 Burrard Street, Suite 500, Vancouver, BC, CAN, V6C 3P6
Zero Candida Technologies Inc is engaged in providing female healthcare solutions. The company technology uses a controlled Blue Light to destroy the fungus at record speed and without side effects. It focused on developing and commercializing several patents and patent applications concerning an AI smart tampon-like device, designed to treat Candidiasis and transfer medical information via Wi-Fi to the doctor.
15GF Score

Get the complete analysis for TSXV:ZCT

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.15
Price